Sarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference
The presentation will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases. For more information, please visit www.sarepta.com.
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com.We encourage investors and potential investors to consult our website regularly for important information about us.
Media and Investors:
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics 2019 Corporate Presentation
Latest Annual Report( FY 2018 )